Overview
Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide derived from the natural polypeptide epithalamin, extracted from the bovine pineal gland. It was developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, where it has been studied since the 1980s as part of a broader program of "peptide bioregulators." Epitalon has attracted research interest primarily due to studies showing telomere elongation in human somatic cells, stimulation of melatonin production, and longevity effects in animal models. Russian clinical studies in elderly subjects are published but not widely replicated in Western peer-reviewed literature.
Mechanism
In cell culture studies, Epitalon has been shown to activate telomerase, the enzyme responsible for telomere elongation, in somatic cells that do not normally express it. This effect has been published in human fetal fibroblast and retinal cell lines. Separately, Epitalon appears to stimulate the pineal gland's melatonin secretion and has been investigated for normalization of the hypothalamic-pituitary axis in aging animal models. Its gene-expression effects are believed to involve histone acetylation changes.
Research Areas
Side Effects (Preclinical)
- – Generally well-tolerated in published Russian clinical studies
- – No serious adverse events reported in the literature
- – Limited independent safety validation
Cautions
- – For research use only — no Western regulatory approval
- – Primary literature is largely from one research group in Russia; independent replication limited
- – Long-term effects of telomerase activation are not fully characterized
Menopause & Women's Health Relevance
Epitalon acts on the pineal gland to restore melatonin production, which declines with age and drops further at menopause — contributing to the sleep disruption, circadian dysregulation, and hot flash-related night waking that characterize this transition. Khavinson's longitudinal studies include post-menopausal women and report reductions in age-related disease biomarkers.
What the research shows
Epitalon’s most striking published finding is the in-vitro telomerase activation in human somatic cells (Khavinson et al., 2003). This result has generated significant interest in the longevity research community, though independent replication in Western labs remains limited.
The body of Epitalon research is primarily from Khavinson’s group in St. Petersburg, spanning 40+ years. Western researchers evaluating this literature should apply standard scrutiny to single-group findings, particularly the longevity claims in long-lived animal strains.
References
- Peptide Epitalon activates telomerase in human somatic cells — Khavinson VKh et al. (2003)
- Pineal-regulating tetrapeptide Epitalon improves eye retina condition in senescence-accelerated mice — Khavinson V et al. (2012)